Key result
Anticoagulation clinic care increases TTR by ~7% versus usual care in low-income heart disease patients.
Why the study?
There is little evidence on the performance of anticoagulation clinics compared to usual medical care in patients on warfarin living in low- and middle-income countries.
Does an anticoagulation clinic improve time in the therapeutic range in low-income Brazilian patients with heart disease on warfarin?
RCT (n=280)
randomly assigned
No
Does an anticoagulation clinic improve time in the therapeutic range in low-income Brazilian patients with heart disease on warfarin?
Implementation of an anticoagulation clinic significantly improved time in the therapeutic range and reduced bleeding complications in a low-income population with heart disease.
Answers are grounded in this paper and cite their sources.
Supports anticoagulation clinic adoption for low-income warfarin patients; extends RCT evidence to resource-limited settings.
Anticoagulation clinics (ACs) have a greater impact on anticoagulation control than usual medical care (UMC). There is little evidence of the performance of AC in patients on warfarin living in low and middle-income countries. We sought to investigate the efficacy and safety of an AC in patients treated at a Brazilian public hospital. This was a randomized clinical trial that tested the efficacy of a recently implemented AC, compared to UMC, in outpatients with heart disease. The primary and secondary endpoints were time in the therapeutic range (TTR) and warfarin-related complications, respectively. Overall, 280 patients were enrolled and randomly assigned to Group A: one year at an AC (A1: first half-year; A2: second half-year); and Group B: first half-year receiving UMC (B1) and second half-year being assisted at the AC (B2). The mean age was 56.8 ± 13.1 years, and most patients were female (54.6%). Above 68% of patients had limited reading capability. A1 demonstrated greater TTR (62.4 ± 20.8%) than B1 (55.1 ± 28.5%) (p = 0.014). Group B improved TTR from 55.1 ± 28.5% (B1) to 62.2 ± 23.1% (B2) (p = 0.008). Despite the underpowered analysis of safety, A1 exhibited a lower incidence rate (IR) per patient-year (p-y) of total bleeding than B1 (incidence rate ratio (IRR): 0.78; p = 0.041) and a reduction in intra-group comparisons (both groups: IRR 0.58; p < 0.001). AC care helped increase TTR in a low-income setting showing favorable performance in a distinct population of those evaluated by previous studies. Extending AC care to similar populations may improve the outcomes of warfarin use.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2023) conducted an RCT in heart disease requiring warfarin (n=280). Anticoagulation clinic (AC) vs. Usual medical care (UMC) was evaluated on time in the therapeutic range (TTR) (p=0.014). Anticoagulation clinic care increased time in the therapeutic range compared to usual medical care in low-income patients with heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: